Chamberlain M C, Levin V A
Department of Neurological Surgery, University of California, San Francisco School of Medicine.
Arch Neurol. 1990 Oct;47(10):1113-6. doi: 10.1001/archneur.1990.00530100081017.
Ten immunocompetent patients with primary non-Hodgkin's lymphoma of the central nervous system were treated by the neuro-oncology service at the University of California at San Francisco (UCSF). After undergoing surgery for biopsy or removal of their tumors, these patients (group 1) received irradiation with hydroxyurea followed by adjuvant chemotherapy with the combination of procarbazine, lomustine (CCNU), and vincristine. The outcome of treatment in this group was compared with that in three other groups of patients with primary CNS lymphoma: patients treated at the UCSF Cancer Research Institute who underwent surgery and radiation therapy (RT) (group 2); patients described in the literature who had surgery and RT (group 3); or patients described in the literature who had surgery, RT, and chemotherapy (group 4). Median and quartile survival times were greater in patients who received adjuvant chemotherapy (group 1, 30 and 50 months; group 4, 20 and 25 months) than in patients who did not receive chemotherapy after RT (group 2, 13 and 20 months; group 3, 15 and 24 months). These results suggest that adjuvant chemotherapy is useful in the treatment of primary CNS lymphoma.
十名患有原发性中枢神经系统非霍奇金淋巴瘤且免疫功能正常的患者在加利福尼亚大学旧金山分校（UCSF）的神经肿瘤学服务部门接受了治疗。这些患者（第1组）在接受手术进行活检或切除肿瘤后，先接受羟基脲放疗，随后接受丙卡巴肼、洛莫司汀（CCNU）和长春新碱联合辅助化疗。将该组患者的治疗结果与其他三组原发性中枢神经系统淋巴瘤患者的治疗结果进行了比较：在UCSF癌症研究所接受手术和放射治疗（RT）的患者（第2组）；文献中描述的接受手术和RT的患者（第3组）；或文献中描述的接受手术、RT和化疗的患者（第4组）。接受辅助化疗的患者（第1组，中位生存期30个月，四分位生存期50个月；第4组，中位生存期20个月，四分位生存期25个月）的中位生存期和四分位生存期比放疗后未接受化疗的患者（第2组，中位生存期13个月，四分位生存期20个月；第3组，中位生存期15个月，四分位生存期24个月）更长。这些结果表明辅助化疗对原发性中枢神经系统淋巴瘤的治疗有用。
